Adalta Ltd
Research Adalta Ltd (1AD) on Bullrun: market cap AUD 9.64M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1AD
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 9.64M
- Financial periodFY2025
- Net income-AUD 4.50M
- Free cash flow-AUD 2.94M
Valuation Snapshot
latest market cap is AUD 9.64M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 4.50M | -AUD 2.94M | n/a | -0.01 | AUD 1.31M | AUD 1.77M | -AUD 598.24K |
| FY2024 | n/a | -AUD 5.38M | -AUD 5.32M | n/a | -0.01 | AUD 3.13M | AUD 2.70M | AUD 2.03M |
| FY2023 | n/a | -AUD 4.85M | -AUD 5.13M | n/a | -0.01 | AUD 4.79M | AUD 4.01M | AUD 1.91M |
| FY2022 | AUD 987.94K | -AUD 6.06M | -AUD 4.11M | 100.0% | -0.02 | AUD 8.74M | AUD 4.00M | AUD 5.38M |
| FY2021 | AUD 848.19K | n/a | n/a | 100.0% | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-08 | AUD 9.64M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adalta Ltd's market cap?
Adalta Ltd's market capitalization is AUD 9.64M.
What does Adalta Ltd do?
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.